Type 2 Diabetes Mellitus affects approximately 20.66 million people across the UK, France, Germany, Spain and Italy1. This leads to many complications including macrovascular and microvascular disease. Glycaemic control in diabetes is particularly important in reducing these complications; a 1% fall in HBA1C results in a 37.5% and 42.5% reduction in microvascular and peripheral vascular disease respectively2.
There are numerous treatments for Type 2 Diabetes Mellitus. These act on receptors within various organs including the pancreas, muscle, adipose tissue, gastrointestinal tract and liver. A new class of drugs, SGLT2-Inhibitors act on the kidney, which itself plays an important role in glycaemic control.
Please note- the EPG Diabetes Webcast Knowledge Centre is not live. Please see the Diabetes and Endocrinology Topic Homepage for related content.
1. IDF Diabetes Atlas 2010. http://www.idf.org/atlasmap/atlasmap. 2. Stratton, I. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412.